Cambodia Pioneers Long-acting HIV Prevention with cabotegravir
Cambodia has taken a notable step forward in its fight against HIV/AIDS, becoming the first nation in the Asia-Pacific region to nationally implement long-acting injectable pre-exposure prophylaxis (PrEP) using Cabotegravir, launched on june 27th. This innovative approach offers a new layer of protection for individuals at risk, bolstering the country’s comprehensive HIV prevention strategy.
A New Era in HIV Prevention
Traditionally, HIV prevention has relied heavily on daily oral PrEP medication. While effective, adherence can be a challenge. Cabotegravir offers a compelling alternative: a single injection administered every two months provides sustained protection against HIV infection. This method is particularly beneficial for populations where consistent daily medication isn’t feasible or preferred.This new preventative measure is targeted towards those most vulnerable to infection, including men who have sex with men, transgender individuals, female sex workers, and people who inject drugs. By providing a discreet and less frequent intervention, CAB-PrEP aims to empower thes communities with greater control over their health.
Impact and Regional Leadership
The introduction of Cabotegravir represents a landmark achievement in Cambodia’s public health initiatives. UNAIDS has lauded the launch as a “historic milestone,” recognizing the nation’s commitment to innovative solutions. Patricia Ongpin, UNAIDS Country Director for Cambodia, Laos and Malaysia, attended the launch event, highlighting the collaborative effort driving this progress.
with a reported 95% effectiveness in preventing HIV transmission, CAB-PrEP expands the toolkit for HIV prevention beyond oral options, offering individuals increased choice and a renewed sense of hope. This proactive approach underscores Cambodia’s position as a regional leader in tackling the HIV/AIDS epidemic.
Current HIV Landscape in cambodia
Recent data from the National AIDS Authority indicates that approximately 76,000 people were living with HIV in Cambodia in 2024. While the overall HIV prevalence remains relatively low at 0.5% of the general population, around 1,200 new infections and 1,000 AIDS-related deaths were recorded during the same period.
Analysis reveals that new infections are disproportionately concentrated among specific demographics, notably young men aged 15-24 engaging in same-sex sexual activity, transgender individuals, and those employed in the entertainment sector. This targeted data informs the strategic deployment of resources and preventative measures like CAB-PrEP.
Progress Towards Global Goals & Future Innovations
Cambodia is demonstrating remarkable progress towards achieving the ambitious global 95-95-95 targets set by UNAIDS.Currently, the nation has reached 92% in knowing one’s HIV status, nearly universal treatment for those diagnosed, and an impressive 98% viral suppression rate among individuals on treatment.Moreover, Cambodia has witnessed a considerable 45% reduction in new HIV infections as 2010 – a rate exceeding the global average. This success is fueled by ongoing commitment and collaboration, exemplified by the recent one-year cooperation agreement between the National AIDS Authority and UNAIDS, including a $100,000 pledge.
Looking ahead,Cambodia is poised to further expand its HIV prevention arsenal with the anticipated rollout of the Dapivirine Vaginal Ring (DVR),a long-acting method specifically designed for women. This continuous pursuit of innovative solutions demonstrates Cambodia’s unwavering dedication to ending the HIV/AIDS epidemic.